XNAS · Healthcare · Biotechnology
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | Q1 2026 | -0.13 | -0.17 | -30.77% | $0 | ❌ Miss | -0.47% | -10.40% | — |
| 2026-03-11 | Q4 2025 | -0.11 | -0.64 | -481.82% | $0 | ❌ Miss | +0.38% | +6.58% | -24.52% |
| 2025-11-05 |
| Q3 2025 |
| -0.35 |
| -0.36 |
| -2.86% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-14 | Q2 2025 | -0.92 | -0.43 | +53.26% | $0 | ✅ Beat | +1.39% | +34.54% | +21.45% |
| 2025-02-25 | Q4 2024 | -1.05 | -0.56 | +46.67% | $0 | ✅ Beat | -2.23% | -11.73% | +1.12% |
| 2024-11-05 | Q3 2024 | -1.01 | 2.97 | +394.06% | $0 | ✅ Beat | -2.12% | -2.12% | -10.17% |
| 2024-08-06 | Q2 2024 | -0.97 | -1.09 | -12.37% | $0 | ❌ Miss | -2.72% | -4.76% | -11.90% |
| 2024-05-01 | Q1 2024 | -1.20 | -1.13 | +5.83% | $0 | ✅ Beat | -2.08% | +4.58% | +6.25% |
Showing last 8 quarters.